MarketPulse
I

$ICCM

6 articles found
5 positive
0 negative
1 neutral
BenzingaBenzinga··Prnewswire

IceCure's ProSense Cryoablation Gains Momentum as Q1 Revenue Surges 30%

IceCure Medical showcased ProSense® cryoablation at breast surgeons conference, reporting 30%+ Q1 revenue growth as adoption accelerates.
ICCMbreast cancerFDA clearance
BenzingaBenzinga··Prnewswire

IceCure's Kidney Cancer Data Shows Strong Promise Ahead of European Presentation

IceCure Medical reports positive 5-year results from ICESECRET trial, demonstrating 83.9% recurrence-free rates in kidney cancer patients using cryoablation technology.
ICCMclinical trialkidney cancer
BenzingaBenzinga··Prnewswire

IceCure Medical Bolsters Leadership Team with CFO, Medical Director Appointments

IceCure Medical ($ICCM) names Meir Peleg as CFO and appoints Dr. Richard Fine as Medical Director, capitalizing on ProSense® cryoablation system's FDA clearance momentum.
ICCMbreast cancerleadership
BenzingaBenzinga··Prnewswire

IceCure Medical to Release 2025 Results March 17, Signaling Year-End Performance Review

IceCure Medical will report 2025 full-year results March 17, 2026, before market open, with a conference call at 11:00 a.m. EDT.
ICCMfinancial resultsearnings announcement
BenzingaBenzinga··Prnewswire

ASBrS Endorses Cryoablation for Low-Risk Breast Cancer, Boosting IceCure Medical

ASBrS endorses cryoablation for low-risk breast cancer, validating IceCure Medical's ProSense system cleared by FDA in October 2025.
ICCMbreast cancerFDA clearance
BenzingaBenzinga··Prnewswire

IceCure's Cryoablation Wins Independent Validation for Breast Fibroadenomas

IceCure's ProSense cryoablation achieved 92.9% volume reduction in independent breast fibroadenoma study, validating technology for a 63,000-patient annual U.S. market.
ICCMmedical deviceminimally invasive surgery